HomeTrading IdeasOperation Midnight Hammer Is...

Operation Midnight Hammer Is Done, Now What?

Markets on Edge: BTC and ETH Stuck as Oil Surges, ETF Hype Builds

A lot just hit the market at once. While crypto’s still stuck in range, two major stories are taking over: rumors of a new ETF approval, and rising geopolitical heat.

The U.S launched Operation Midnight Hammer, targeting three Iranian nuclear sites. In response, Iran moved fast and now plans to close the Strait of Hormuz, which is one of the world’s key oil routes. jumped, markets tensed up, and crypto’s now caught in the middle.

BTC and ETH: $100K Break Fails to Hold, Momentum Fades

broke below the $100,000 level yesterday, sliding down to around $98,250 before finding temporary support. The move shook up bullish sentiment, not because of the drop itself, but because $100K had become a key psychological level. Losing it so easily signals weakness, not strength.

followed the same pattern. It dropped to around $2,115, failing to defend the $2,200–$2,300 zone that traders had hoped would hold during ETF speculation. Despite the narrative, there’s no real follow-through yetETH Chart - Scenario 2

For now, both BTC and ETH are stuck in soft territory. Funding rates remain neutral to slightly positive, but without momentum, the market feels more hesitant than confident waiting for a trigger to move decisively again.BTC/USD Chart

Strait of Hormuz Closure Sends Oil Higher

After the US strike on Iranian nuclear sites, Iran wants to retaliate by having the Strait of Hormuz closed, a key route for global oil shipments. Over 20% of the world’s oil moves through it.

Oil prices jumped right after, raising concerns about inflation and supply disruptions. For crypto, that’s pressure. Rising oil often leads to tighter monetary policy, which usually weighs on risk assets like BTC and ETH.

Interestingly, Trump has long favored higher oil prices to support U.S. energy producers. So while the strike raises global risks, some might see this as a geopolitical win-win for the U.S.

ETH and Altcoin ETF Rumors Surface

Bloomberg’s James Seyffart mentioned in a tweet that the SEC approval may be happening to spot ETFs for a broader list of tokens including Ethereum, , , , , and others.

There’s no official confirmation yet, and markets haven’t reacted meaningfully. For now, it’s just worth watching.

Final Take

Crypto’s stuck in a holding pattern. BTC lost $100K, ETH is flat, and ETF rumors alone aren’t moving the market. Meanwhile, the Strait of Hormuz is closed, oil is slowly rising, and macro risk is back on the table.

It’s the kind of setup where nothing happens until it suddenly does.

Disclosure: This content is for educational purposes only and does not constitute investment advice. Always DYOR,  Do Your Own Research.

Cryptocurrencies are subject to high market risk and vulnerability, despite their high growth potential. Users are strongly advised to conduct thorough research and invest at their own risk.

Most Popular

More from Author

The Bull Market Is Alive and Well

The bull market is alive and well, even amid widespread talk...

Why Is Jasper Therapeutics Stock Falling On Monday? – Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics, Inc. JSPR stock is experiencing a steep decline on...

Stocks Wobble as Trump Resurrects Tariff Threats Ahead of July 9 Deadline

Market participants were expecting an upbeat start to the week on...

Read Now

Trump’s New Tariffs Shake Markets as Yen and ETFs Slide – iShares MSCI Japan Index Fund (ARCA:EWJ), iShares MSCI Malaysia Index Fund (ARCA:EWM)

The U.S. dollar is notching its strongest one-day gain against the Japanese yen in nearly two months as traders react to President Donald Trump's sweeping new tariffs targeting multiple U.S. trading partners.Starting Aug. 1, all goods imported from Japan and other Asian trading partners will face a...

The Bull Market Is Alive and Well

The bull market is alive and well, even amid widespread talk of the “death of U.S. exceptionalism.” Early 2025 saw a sharp shift in investor sentiment. Concerns over erratic trade policy, soaring debt, and weakening pressure challenged America’s long-standing market dominance. Markets fell sharply in April...

Why Is Jasper Therapeutics Stock Falling On Monday? – Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics, Inc. JSPR stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro.What Happened?The company...

Stocks Wobble as Trump Resurrects Tariff Threats Ahead of July 9 Deadline

Market participants were expecting an upbeat start to the week on the hope that trade deals might finally be announced as the Trump administration deadline of July 9 approaches. However, President Trump adopted a confrontational stance once more by announcing that the US will begin issuing tariff...

CAD/JPY Ready to Continue Rising Ahead of Employment Change and Unemployment Rate

For three months since April, the currency has shown strength against the . although at the moment the price still cannot break the small resistance area on the H4 timeframe. but it is expected that the fundamental impulses can move the market more significantlyFigure 1. CAD/JPY...

What’s Going On With Hims & Hers Health Stock On Monday? – Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges.A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S...

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder. With statistically significant improvements across all endpoints—including symptom reduction and biomarkers of mast cell activity—the data support the company's plan to file for Food and Drug Administration...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups are emerging—each supported by seasonal patterns and historical data. is approaching multi-year highs following a strong June, while technical signals in the broader market and semiconductor sector point to continued momentum. Meanwhile, recent policy developments may...

The Energy Report: Listen to What OPEC Says

prices are shaking off a larger-than-expected OPEC production increase as the precious metals get hit by a ton of bricks after President Trump posted about new tariffs on BRIC Nations on his Truth Social account. Yet despite the talk about OPEC wanting to maintain its market share,...

Why Is KalVista Pharmaceuticals Stock Soaring On Monday? – KalVista Pharma (NASDAQ:KALV)

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals Inc.’s KALV Ekterly (sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.Ekterly is the first and only oral on-demand treatment for HAE. HAE is characterized by recurrent...

Dow Jones Forecast: Political Tensions and Tariff Risks Weigh on Outlook

US futures are rising on Monday after the extended holiday weekend. Uncertainty surrounding U.S. trade tariff policies are keeping investors cautious, whilst Tesla (NASDAQ:) is taking a hit after Musk announced plans to launch a political party.US Futures 0.78% at 44839 0.7% at 6266 0.53% at 23977In...

Why Is Apogee Therapeutics Stock Soaring On Monday? – Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics Inc. APGE stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday.This substantial increase in stock price follows the release of positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody, for moderate-to-severe...